, Tracking Stock Market Picks
Enter Symbol:
Cytrx Corporation (CYTR) [hlAlert]

Mkt Outperform
down 51.96 %

Cytrx Corporation (CYTR) rated Mkt Outperform with price target $7 by Rodman & Renshaw

Posted on: Monday,  Sep 10, 2012  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Cytrx Corporation (NASDAQ: CYTR) on 09/10/2012. Previously Rodman & Renshaw rated Mkt Outperform Cytrx Corporation (NASDAQ: CYTR)
on 06/08/2009., when the stock price was $4.83. Since then, Cytrx Corporation has lost 51.97% as of 01/26/2016's recent price of $2.32.
If you would have followed the previous Rodman & Renshaw's recommendation on CYTR, you would have lost 51.96% of your investment in 2423 days.

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/10/2012 8:25 AM Buy
4.29 7.00
as of 12/31/2012
1 Week down  -1.57 %
1 Month down  -7.42 %
3 Months down  -48.48 %
1 YTD down  -4.59 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/8/2009 11:25 AM Buy
4.83 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy